Murillo-Godínez G

Language: Spanish
References: 10
Page: 226
PDF size: 83.33 Kb.

Text Extraction

No abstract

REFERENCES

1. Murillo-Godínez G. ¿Cuánto es hipocolesterolemia y las patologías asociadas? Rev Med Inst Mex Seguro Soc 2009;47(1):4-6.

2. Pérez-Guzmán C, Vargas MH, Torres-Cruz A, Villarreal-Velarde H. Tuberculosis miliar en tuberculosis de reactivación. Informe de 36 pacientes y comparación con las formas puras. Rev Inst Nac Enf Respir 1999;12:19-28.

3. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-1060

4. Mahley RW, Bersot TP. Farmacoterapia para hipercolesterolemia y dislipidemia. En: Brunton LL, Lazo JS, Parker KL, editores. Goodman and Gilman. Las bases farmacológicas de la terapéutica. México: McGraw-Hill Interamericana; 2007. p. 945.

5. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-282.

6. Welty FK, Lahoz C, Tucker KL, et al. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol 1998;18:1745-1751.

7. Appleby PN, Thorogood M, Mann JJ, Key TJ. The Oxford Vegetarian Study: an overview. Am J Clin Nutr 1999;70(suppl): 525S-531S.

8. Neaton JD, Blackburn H, Jacobs D. Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Arch Intern Med 1992;152:1490-1500.

9. Grundy SM, Cleeman JI, Merz CN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.

10. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-379.